Tickers

1. Composite Trajectory Verdict

All three statements carry roughly equal weight: the income statement shows whether the core travel-management platform generates operating leverage, the cash flow statement reveals if that leverage converts to discretionary cash after heavy capex and restructuring outlays, and the balance sheet tracks the integration of large acquisitions (CWT, Uvet GBT) and the evolution of leverage.

Composite Trajectory: Mixed

Revenue growth is strong on both an annual (+12% to $2.718B in FY2025) and quarterly basis (+38% to $870M in Q2 2026, +37% to $1.710B YTD), but it is heavily acquisition-driven (CWT contributed ~12% of annual TTV growth and 41-43% of quarterly TTV growth). GAAP operating income fell 29% in Q2 2026 ($24M vs $34M) and 69% YTD ($27M vs $89M) as total operating expenses outpaced revenue (42-45% vs 37-38%). Gross margin compressed annually (57% vs 58%) and quarterly (56-57% vs 59%). Net income swung positive annually ($111M vs -$134M) but declined YTD ($71M vs $90M). Free cash flow fell 37% annually ($104M vs $165M) and was flat YTD ($51M vs $53M), though Q2 alone surged ($103M vs $27M). Net debt crept up ($984M to $994M) while the earnout derivative liability was eliminated ($37M to $0). The picture is therefore split: top-line expansion and GAAP profitability improvement year-over-year, but deteriorating operating leverage, margin compression, and rising leverage in the most recent quarters.

2. Red Flags

• Operating expense growth exceeded revenue growth in Q2 2026 (42% vs 38%) and YTD (45% vs 37%), driving operating income down 29% and 69% respectively (10-Q Q2 2026, Condensed Statements of Operations).
• Gross margin compressed 15 bps annually (57% vs 58%) and 200-300 bps quarterly (56-57% vs 59%) (10-K FY2025, Key Financial Metrics; 10-Q Q2 2026, Key Financial Metrics).
• Restructuring charges jumped to $52M in FY2025 from $17M in FY2024 (10-K FY2025, Results of Operations) and to $85M in H1 2026 from $16M in H1 2025 (10-Q Q2 2026, Restructuring and Other Exit Charges), indicating recurring "non-recurring" costs.
• Free cash flow declined 37% annually ($104M vs $165M) and was flat YTD ($51M vs $53M) despite higher EBITDA (10-K FY2025, Key Financial Metrics; 10-Q Q2 2026, Free Cash Flow).
• Net debt increased $136M in FY2025 ($984M vs $848M) and a further $10M in H1 2026 ($994M vs $984M) (10-K FY2025, Net Debt; 10-Q Q2 2026, Net Debt).
• Earnout derivative liability valuation shifted from a $56M charge in FY2024 to a $96M gain in FY2025, then to a $6M gain in Q2 2026 after a methodology change tied to the pending merger (10-K FY2025, Fair Value Movements; 10-Q Q2 2026, Fair Value Movement).
• Share repurchase program ($300M authorized) was terminated in May 2026 upon signing the merger agreement (10-Q Q2 2026, Share Repurchase Program).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results improved markedly: revenue rose 12% to $2.718B, operating income rose 13% to $130M, and net income swung to $111M from a -$134M loss (10-K FY2025, Consolidated Statements of Operations). However, quarterly trends show deterioration: Q2 2026 operating income fell 29% to $24M on 38% revenue growth, and YTD operating income fell 69% to $27M on 37% revenue growth (10-Q Q2 2026, Consolidated Statements of Operations). Gross margin compressed from 58% to 57% annually and from 59% to 56-57% quarterly (10-K FY2025, Key Financial Metrics; 10-Q Q2 2026, Key Financial Metrics). Net income declined YTD to $71M from $90M despite higher revenue (10-Q Q2 2026, Consolidated Statements of Operations). Adjusted EBITDA margin held near 20% annually but slipped to 19% YTD from 22% (10-K FY2025, Key Financial Metrics; 10-Q Q2 2026, Key Financial Metrics).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow declined 15% to $233M from $272M, and free cash flow fell 37% to $104M from $165M (10-K FY2025, Cash Flows). The decline was driven by $74M working capital outflows including higher tax and M&A payments, partially offset by $35M from interest-rate swap terminations (10-K FY2025, Cash Flows). Quarterly trends reversed: Q2 2026 operating cash flow surged 153% to $142M and free cash flow jumped to $103M from $27M (10-Q Q2 2026, Cash Flows). YTD operating cash flow rose modestly 16% to $127M, but free cash flow was flat at $51M vs $53M due to a $19M increase in capex (10-Q Q2 2026, Free Cash Flow). Investing cash outflows doubled annually to $206M (driven by $138M CWT acquisition, net of cash) and rose 36M YTD to $66M (10-K FY2025, Cash Flows; 10-Q Q2 2026, Cash Flows). Financing flows reflected $100M incremental term loan borrowing in January 2026 and $47M of share repurchases before program termination (10-Q Q2 2026, Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 36% annually to $4.916B (driven by CWT/Uvet GBT goodwill +$470M and intangibles +$371M) and 3% quarterly to $5.077B (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Total liabilities rose 27% annually to $3.255B and 4% quarterly to $3.386B. Long-term debt increased from $1.365B to $1.360B annually (flat) then to $1.451B quarterly (+$91M net of discount/issuance costs) after the $100M incremental borrowing (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Cash fell 19% annually to $434M but rebounded 19% quarterly to $518M (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Net debt rose from $848M to $984M annually and to $994M quarterly (10-K FY2025, Net Debt; 10-Q Q2 2026, Net Debt). The earnout derivative liability was eliminated ($37M to $0) in Q2 2026 following a valuation methodology change tied to the pending merger (10-Q Q2 2026, Consolidated Balance Sheets). Shareholders' equity grew 53% annually to $1.612B (aided by $408M share issuance for CWT) and 2% quarterly to $1.645B (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets).

6. Data Gaps

• Standalone Q3 2025 and Q4 2025 quarterly results (to separate acquisition impact from organic trends)
• Full-year 2023 income statement and cash flow detail (only summary figures in 10-K)
• Organic revenue growth rate excluding CWT and Uvet GBT contributions for each quarter
• Detailed breakdown of restructuring charges by segment and expected future run-rate
• Covenant headroom calculations under the Amended Credit Agreement (only compliance stated)
• Post-merger pro forma financials (merger expected to close H2 2026)